Federal Trade Commission Preserves Competition for Development and Marketing of Steroid Injectable Drug
Date
The Federal Trade Commission today required – as a condition of Hikma Pharmaceuticals PLC’s $375 million acquisition of Custopharm, Inc. – that Custopharm’s parent company retain and transfer...